Related Experiment Video
Updated: Jun 22, 2026
11:02
Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
Tailored PEG for rh-G-CSF analogue site-specific conjugation
Stefano Salmaso1, Sara Bersani, Anna Scomparin
1Department of Pharmaceutical Sciences, University of Padua, Via F. Marzolo, 5, 35131 Padova, Italy.
Bioconjugate Chemistry
|May 28, 2009
Summary
A novel PEGylation strategy using PEG-C(18)-Mal enhances protein stability and conjugation efficiency for recombinant human granulocyte colony stimulating factor (rh-G-CSF). This method offers superior stability compared to standard PEG-Mal under native conditions.
Area of Science:
- Bioconjugation Chemistry
- Protein Engineering
- Polymer Chemistry
Background:
- Site-directed protein PEGylation is crucial for improving therapeutic protein properties.
- Existing PEGylation reagents like maleimido-activated PEG (PEG-Mal) have limitations in efficiency and protein stability under native conditions.
- Developing novel PEG derivatives is essential for advanced bioconjugation applications.
Purpose of the Study:
- To synthesize and characterize a new end-tailored monomethoxypoly(ethylene glycol) (PEG-C(18)-Mal) for site-directed protein conjugation.
- To evaluate the conjugation efficiency and stability of rh-G-CSF PEGylated with PEG-C(18)-Mal compared to commercial PEG-Mal.
- To assess the impact of PEGylation on protein secondary structure and stability.
Main Methods:
- A three-step synthesis was employed to create PEG-C(18)-Mal from linear 20 kDa PEG-NH(2).
- Purification and characterization using solvent precipitation/extraction and (1)H NMR spectroscopy.
- Conjugation of PEG-C(18)-Mal and PEG-Mal to cysteine 17 of rh-G-CSF under denaturing and native conditions, followed by stability assessment via aggregation assays and circular dichroism.
Main Results:
- The synthesis yielded over 90% activated PEG-C(18)-Mal product.
- Under native conditions, PEG-C(18)-Mal achieved 55% protein conjugation, significantly higher than PEG-Mal (7%).
- PEGylated rh-G-CSF with PEG-C(18)-Mal in the absence of denaturants showed a remarkable aggregation half-life of 60 hours, compared to 30-90 minutes for other derivatives.
Conclusions:
- The novel PEG-C(18)-Mal is an effective reagent for site-directed protein PEGylation, offering superior conjugation efficiency under native conditions.
- PEGylation using PEG-C(18)-Mal significantly enhances the stability of rh-G-CSF, preventing rapid aggregation.
- This advanced PEGylation approach holds promise for developing more stable and effective protein therapeutics.
